Yorvipath (palopegteriparatide) — Medica

Initial criteria

• Patient cannot be well-controlled on calcium supplements and active forms of vitamin D according to the prescriber
• Patient has sufficient 25-hydroxyvitamin D stores at baseline before initiating Yorvipath therapy according to the prescriber
• Patient meets ONE of the following: (a) albumin-corrected serum calcium concentration ≥ 7.8 mg/dL at baseline before initiating Yorvipath therapy OR (b) ionized serum calcium ≥ 4.4 mg/dL at baseline before initiating Yorvipath therapy
• Medication is prescribed by or in consultation with an endocrinologist or a nephrologist

Reauthorization criteria

• Patient cannot be well-controlled on calcium supplements and active forms of vitamin D according to the prescriber
• Patient has sufficient 25-hydroxyvitamin D stores during Yorvipath therapy according to the prescriber
• Patient is responding to Yorvipath therapy according to the prescriber (response includes reduction in oral calcium dose, reduction in active vitamin D dose, and maintenance of stable albumin-corrected total serum calcium concentration)

Approval duration

1 year